MNOV Latest Press Releases

-- September 24, 2026 --

MediciNova Announces Completion of Last Patient, Last Visit in the Double-Blind Portion of the Phase 2b/3 COMBAT-ALS Trial of MN-166 (Ibudilast) Globe Newswire 6:00 AM

-- September 8, 2026 --

MediciNova to Participate in Two Investor Conferences in September Globe Newswire 6:00 AM

-- July 15, 2026 --

MediciNova Announces Patient Enrollment Milestone Achieved in SEANOBI Study Expanded-Access-Program Evaluating MN-166 (ibudilast) in ALS patients Globe Newswire 8:00 AM

-- June 30, 2026 --

MediciNova CEO Provides Shareholder Update Globe Newswire 8:00 AM

-- June 8, 2026 --

MediciNova Receives Notice of Allowance for New Patent Covering Use of MN-166 in Combination with Anti-PD-1 Immune Checkpoint Inhibitor for Glioblastoma Treatment Globe Newswire 8:00 AM

-- May 26, 2026 --

MediciNova Announces Completion of Last Patient Last Visit in the MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast) Globe Newswire 7:00 PM

-- April 27, 2026 --

New Peer-Reviewed Study Reveals Actionable Immune-Microenvironment Target in Brain Metastasis; Medicinova Advances Clinical Translation Globe Newswire 7:00 PM

Market Data Delayed 15 Minutes

Questions? Feedback?Olark live chat software